✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
BC-3781 is an investigational drug.
There have been 5 clinical trials for BC-3781. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2016.
The most common disease conditions in clinical trials are Pneumonia, Bacterial, Pneumonia, and Infections. The leading clinical trial sponsors are Nabriva Therapeutics AG and [disabled in preview].
There are ten US patents protecting this investigational drug and one hundred and fifty-six international patents.
Recent Clinical Trials for BC-3781
|Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis||Nabriva Therapeutics AG||Phase 1|
|Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia||Nabriva Therapeutics AG||Phase 3|
|Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia||Nabriva Therapeutics AG||Phase 3|
Top disease conditions for BC-3781
Top clinical trial sponsors for BC-3781
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|BC-3781||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|BC-3781||See Plans and Pricing||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|BC-3781||See Plans and Pricing||Compartmented pharmaceutical dosage forms||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|BC-3781||See Plans and Pricing||Crystal structure of the large ribosomal subunit from S. aureus||Yeda Research and Development Co. Ltd. (Rehovot, IL)||See Plans and Pricing|
|BC-3781||See Plans and Pricing||Process for preparing pleuromutilin||California Institute of Technology (Pasadena, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|BC-3781||Australia||AU2017261372||2036-05-05||See Plans and Pricing|
|BC-3781||Canada||CA3023278||2036-05-05||See Plans and Pricing|
|BC-3781||China||CN107847398||2036-05-05||See Plans and Pricing|
|BC-3781||European Patent Office||EP3452003||2036-05-05||See Plans and Pricing|
|BC-3781||European Patent Office||EP3981392||2036-05-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|